NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J.
Cecchini M, et al. Among authors: kortmansky js.
Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22.
Br J Cancer. 2024.
PMID: 38135713
Free PMC article.
Clinical Trial.